Rexam to close Nashua plant; appoints new CEO

By Gareth Macdonald

- Last updated on GMT

Rexam will close its pill and tablet bottle making facility in New Hampshire, US by the end of the year to further align global plastics operations according to new CEO Graham Chipchase

Chipchase, who took over from Leslie Van de Walle on January 1, said closure of the facility in Nashua will “improve overall utilisation of our existing operations [and] further balance capacity and demand​.”

The plant, which was gain through Rexam’s acquisition of Owens-Illinois in 2007​, employs a staff of 100 people in the production of tablet and pill bottles from high-density polyethylene and polypropylene resins.

In a press statement, Rexam said that production operations at Nashua will be transferred to its other manufacturing plants over the next few months without impacting on current shipments.

Rexam has been reducing capacity across its healthcare, personal care and food packaging manufacturing operations over the last few months, primarily as a result of a drop in demand for beverage packaging.

This process began in October last year with the closure of a moulded-packaging facility in Holden, Massachusetts.

The firm subsequently announced plans to close a plant that makes foam pump dispensers in Florida and a food packaging facility in North Carolina by the end of the first quarter this year.

And, in late December, Rexam agreed to sell an injection moulding plant in Sussex, Wisconsin to a group led by the former manager of its personal care unit, Keith Everson.

Related news

Related products

show more

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more